Lung Cancer Clinical Trial

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy

Summary

This observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer. Patients will be enrolled prior to the start of therapy and followed during and for at least 2 years after therapy with echocardiograms, nuclear stress tests, blood sampling, and quality of life surveys.

View Full Description

Full Description

Lung cancer is both the most common malignancy worldwide and the leading cause of cancer death in the US. While radiation therapy is highly effective for many solid tumors, thoracic radiation therapy carries a risk of cardiovascular morbidity and mortality that limits critical gains in cancer control and survival. The investigators will perform detailed cardiovascular phenotyping using biologic and imaging markers to define functional and physiologic perturbations that occur with radiation therapy. The study will provide insights into how cardiovascular risk factors and disease impact these biologic and functional changes. The investigators will also determine which radiotherapy dose-volume metrics are indicative of subclinical cardiotoxicity.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

At least 18 years of age
Histologically confirmed, locally advanced Stage II, IIIA, or IIIB non-small cell lung cancer with inoperable disease
Planned to receive treatment with definitive concurrent chemoradiation with curative intent
Able to give written informed consent

Exclusion Criteria:

Pregnant or breast-feeding
Prior thoracic radiotherapy that would result in overlap of radiation therapy in the heart
Prior treatment with anthracyclines
ECOG performance status greater than 2
Vulnerable patients, including pregnant women and prisoners
Contraindication to rest/vasodilator stress PET/CT, including: asthma with ongoing wheezing at time of enrollment; known 2nd or 3rd degree atrioventricular block without a pacemaker, or sick sinus syndrome; systolic blood pressure less than 90mmHg; known hypersensitivity to Regadenoson or adenosine; profound sinus bradycardia (heart rate less than 40bpm).

Study is for people with:

Lung Cancer

Estimated Enrollment:

221

Study ID:

NCT04305613

Recruitment Status:

Enrolling by invitation

Sponsor:

Abramson Cancer Center of the University of Pennsylvania

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

University of Alabama
Birmingham Alabama, 35233, United States
The Brigham and Women's Hospital
Boston Massachusetts, 02115, United States
Washington University School of Medicine
Saint Louis Missouri, 63110, United States
Rutger's University / Cancer Institute of New Jersey
New Brunswick New Jersey, 08901, United States
Montefiore Medical Center
Bronx New York, 19046, United States
Abramson Cancer Center of the University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States
Chester County Hospital
West Chester Pennsylvania, 19380, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Estimated Enrollment:

221

Study ID:

NCT04305613

Recruitment Status:

Enrolling by invitation

Sponsor:


Abramson Cancer Center of the University of Pennsylvania

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.